PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis DOI

Junwei Hou,

Rongce Zhao,

Weiya Xia

et al.

Nature Cell Biology, Journal Year: 2020, Volume and Issue: 22(10), P. 1264 - 1275

Published: Sept. 14, 2020

Language: Английский

Elements of cancer immunity and the cancer–immune set point DOI
Daniel S. Chen, Ira Mellman

Nature, Journal Year: 2017, Volume and Issue: 541(7637), P. 321 - 330

Published: Jan. 1, 2017

Language: Английский

Citations

4327
Tumour-associated macrophages as treatment targets in oncology DOI
Alberto Mantovani, Federica Marchesi, Alberto Malesci

et al.

Nature Reviews Clinical Oncology, Journal Year: 2017, Volume and Issue: 14(7), P. 399 - 416

Published: Jan. 24, 2017

Language: Английский

Citations

3260
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies DOI
Jérôme Galon, Daniela Bruni

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(3), P. 197 - 218

Published: Jan. 4, 2019

Language: Английский

Citations

2639
Immunogenic cell death in cancer and infectious disease DOI
Lorenzo Galluzzi,

Aitziber Buqué,

Oliver Kepp

et al.

Nature reviews. Immunology, Journal Year: 2016, Volume and Issue: 17(2), P. 97 - 111

Published: Oct. 17, 2016

Language: Английский

Citations

2435
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy DOI
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders

et al.

Nature reviews. Cancer, Journal Year: 2016, Volume and Issue: 16(5), P. 275 - 287

Published: April 15, 2016

Language: Английский

Citations

2405
The immune contexture in cancer prognosis and treatment DOI
Wolf H. Fridman, Laurence Zitvogel, Catherine Sautès‐Fridman

et al.

Nature Reviews Clinical Oncology, Journal Year: 2017, Volume and Issue: 14(12), P. 717 - 734

Published: July 25, 2017

Language: Английский

Citations

1889
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study DOI
Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei

et al.

The Lancet Oncology, Journal Year: 2016, Volume and Issue: 17(11), P. 1497 - 1508

Published: Oct. 12, 2016

Language: Английский

Citations

1315
Tertiary lymphoid structures in the era of cancer immunotherapy DOI
Catherine Sautès‐Fridman, Florent Petitprez, Julien Caldéraro

et al.

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 19(6), P. 307 - 325

Published: May 15, 2019

Language: Английский

Citations

1308
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy DOI
Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa

et al.

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(6), P. 356 - 371

Published: Jan. 31, 2019

Language: Английский

Citations

1198
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data DOI Creative Commons
Francesca Finotello, Clemens Mayer, Christina Plattner

et al.

Genome Medicine, Journal Year: 2019, Volume and Issue: 11(1)

Published: May 24, 2019

We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry, immunohistochemistry data.quanTIseq analysis 8000 revealed that cytotoxic T infiltration is more strongly associated with activation CXCR3/CXCL9 axis than mutational load deconvolution-based scores have prognostic value several solid cancers. Finally, we used show how kinase inhibitors modulate contexture reveal immune-cell underlie differential patients' responses checkpoint blockers.Availability: available at http://icbi.at/quantiseq .

Language: Английский

Citations

1138